About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT01960634

Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma

This is a multi-centric translational study with biological samples collection. The aim of this study is to validate a method to detect BRAFV600 in blood samples. Samples: Blood from patients with BR...

Lead sponsor: Grupo Español Multidisciplinar de Melanoma•13 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Grupo Español Multidisciplinar de Melanoma

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Confirmed diagnosis of melanoma and BRAFV600
•Signed Informed Consent Form
•Unresectable phase III or phase IV melanoma
•The patients should be starting a treatment for melanoma (either first line or subsequent lines)

Related studies

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

NCT03154190 · Acute Myeloid Leukemia, Brain Glioblastoma, and more

COMPLETEDPhase 1

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

NCT03229278 · Lymphoma, Metastatic Malignant Solid Neoplasm, and more

Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners

NCT03112668 · Malignant Female Reproductive System Neoplasm, Malignant Hepatobiliary Neoplasm, and more

TERMINATEDPhase 2

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

NCT01970527 · Recurrent Melanoma, Stage IV Skin Melanoma

COMPLETEDPhase 1/2

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

NCT01196416 · Recurrent Melanoma, Stage IV Skin Melanoma

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 5, 2015Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment58

Start dateApr 2013

Last updatedMay 5, 2015

Condition

Stage IV Skin Melanoma

Locations shown

Hospital Infanta Cristina

Madrid, Badajoz

Hospital Germans Trias i Pujol

Badalona, Barcelona

Hospital del Mar

Barcelona, Barcelona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 5, 2015Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions